NZ508386A - 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide for treating diseases associated with neurokinin-1 (NK-1) activity - Google Patents

2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide for treating diseases associated with neurokinin-1 (NK-1) activity

Info

Publication number
NZ508386A
NZ508386A NZ508386A NZ50838600A NZ508386A NZ 508386 A NZ508386 A NZ 508386A NZ 508386 A NZ508386 A NZ 508386A NZ 50838600 A NZ50838600 A NZ 50838600A NZ 508386 A NZ508386 A NZ 508386A
Authority
NZ
New Zealand
Prior art keywords
diseases associated
treating diseases
isobutyramide
neurokinin
morpholin
Prior art date
Application number
NZ508386A
Other languages
English (en)
Inventor
Theresa Maria Ballard
Guy Andrew Higgins
Torsten Hoffmann
Sonia Maria Poli
Andrew Sleight
Original Assignee
F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F filed Critical F
Publication of NZ508386A publication Critical patent/NZ508386A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ508386A 1999-11-29 2000-11-23 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide for treating diseases associated with neurokinin-1 (NK-1) activity NZ508386A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
NZ508386A true NZ508386A (en) 2003-02-28

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ508386A NZ508386A (en) 1999-11-29 2000-11-23 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide for treating diseases associated with neurokinin-1 (NK-1) activity

Country Status (49)

Country Link
EP (1) EP1103545B1 (cg-RX-API-DMAC7.html)
JP (1) JP3480835B2 (cg-RX-API-DMAC7.html)
KR (1) KR100390117B1 (cg-RX-API-DMAC7.html)
CN (1) CN1152016C (cg-RX-API-DMAC7.html)
AR (1) AR033659A1 (cg-RX-API-DMAC7.html)
AT (1) ATE253561T1 (cg-RX-API-DMAC7.html)
AU (1) AU775292B2 (cg-RX-API-DMAC7.html)
BG (1) BG64622B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0005616B8 (cg-RX-API-DMAC7.html)
CA (1) CA2326529C (cg-RX-API-DMAC7.html)
CO (1) CO5251405A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ299286B6 (cg-RX-API-DMAC7.html)
DE (2) DE60006340T2 (cg-RX-API-DMAC7.html)
DK (1) DK1103545T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2000000106A (cg-RX-API-DMAC7.html)
EA (1) EA004404B1 (cg-RX-API-DMAC7.html)
ES (2) ES2208205T3 (cg-RX-API-DMAC7.html)
FR (1) FR2801590A1 (cg-RX-API-DMAC7.html)
GB (1) GB2356863A (cg-RX-API-DMAC7.html)
GC (1) GC0000151A (cg-RX-API-DMAC7.html)
GE (1) GEP20022763B (cg-RX-API-DMAC7.html)
GT (1) GT200000197A (cg-RX-API-DMAC7.html)
HR (1) HRP20000809A2 (cg-RX-API-DMAC7.html)
HU (1) HU224703B1 (cg-RX-API-DMAC7.html)
ID (1) ID28483A (cg-RX-API-DMAC7.html)
IL (1) IL139868A (cg-RX-API-DMAC7.html)
IS (1) IS2212B (cg-RX-API-DMAC7.html)
IT (1) IT1320120B1 (cg-RX-API-DMAC7.html)
JO (1) JO2298B1 (cg-RX-API-DMAC7.html)
MA (1) MA26754A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA00011672A (cg-RX-API-DMAC7.html)
MY (1) MY127426A (cg-RX-API-DMAC7.html)
NO (1) NO317264B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ508386A (cg-RX-API-DMAC7.html)
OA (1) OA11513A (cg-RX-API-DMAC7.html)
PA (1) PA8507201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20010901A1 (cg-RX-API-DMAC7.html)
PL (1) PL195957B1 (cg-RX-API-DMAC7.html)
PT (1) PT1103545E (cg-RX-API-DMAC7.html)
SG (1) SG97171A1 (cg-RX-API-DMAC7.html)
SI (1) SI1103545T1 (cg-RX-API-DMAC7.html)
SK (1) SK285373B6 (cg-RX-API-DMAC7.html)
SV (1) SV2002000227A (cg-RX-API-DMAC7.html)
TN (1) TNSN00226A1 (cg-RX-API-DMAC7.html)
TR (1) TR200302077T4 (cg-RX-API-DMAC7.html)
UA (1) UA70326C2 (cg-RX-API-DMAC7.html)
UY (1) UY26458A1 (cg-RX-API-DMAC7.html)
YU (1) YU73400A (cg-RX-API-DMAC7.html)
ZA (1) ZA200006964B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2238264C2 (ru) 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
EP1303490B1 (en) * 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
PL371731A1 (en) * 2002-01-31 2005-06-27 F.Hoffmann-La Roche Ag Genetic polymorphisms in the preprotachykinin gene
HRP20070471T3 (hr) 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
EP1776342B1 (en) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
CA2602445C (en) 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
NZ566419A (en) 2005-09-23 2010-03-26 Hoffmann La Roche Novel dosage formulation
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015068744A1 (ja) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
DK3102208T4 (da) 2014-02-07 2024-08-26 Global Blood Therapeutics Inc Krystallinsk polymorph af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919245A3 (en) * 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE364606T1 (de) * 1993-12-29 2007-07-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als arzneimittel
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
NO309272B1 (no) * 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
EP1303490B1 (en) * 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
CZ20004399A3 (cs) 2001-07-11
IT1320120B1 (it) 2003-11-18
EA004404B1 (ru) 2004-04-29
CN1297888A (zh) 2001-06-06
AU775292B2 (en) 2004-07-29
GEP20022763B (en) 2002-08-26
IL139868A0 (en) 2002-02-10
HUP0004725A2 (hu) 2002-04-29
BRPI0005616B1 (pt) 2017-12-12
JP2001151754A (ja) 2001-06-05
KR20010051983A (ko) 2001-06-25
SG97171A1 (en) 2003-07-18
MXPA00011672A (es) 2002-08-20
HU224703B1 (en) 2006-01-30
DK1103545T3 (da) 2004-03-15
CA2326529A1 (en) 2001-05-29
IS2212B (is) 2007-02-15
HK1036759A1 (en) 2002-01-18
CZ299286B6 (cs) 2008-06-04
IL139868A (en) 2009-09-01
PT1103545E (pt) 2004-03-31
CO5251405A1 (es) 2003-02-28
MY127426A (en) 2006-11-30
NO317264B1 (no) 2004-09-27
HU0004725D0 (cg-RX-API-DMAC7.html) 2001-02-28
AR033659A1 (es) 2004-01-07
SV2002000227A (es) 2002-02-05
BG64622B1 (bg) 2005-09-30
PA8507201A1 (es) 2002-02-21
CA2326529C (en) 2009-12-22
FR2801590A1 (fr) 2001-06-01
SK17932000A3 (sk) 2001-11-06
TNSN00226A1 (fr) 2002-05-30
PL344147A1 (en) 2001-06-04
EA200001114A3 (ru) 2001-12-24
PL195957B1 (pl) 2007-11-30
KR100390117B1 (ko) 2003-07-04
JO2298B1 (en) 2005-09-12
MA26754A1 (fr) 2004-12-20
PE20010901A1 (es) 2001-09-20
DOP2000000106A (es) 2002-07-30
DE60006340D1 (de) 2003-12-11
UY26458A1 (es) 2001-05-31
DE10058310A1 (de) 2001-05-31
CN1152016C (zh) 2004-06-02
EA200001114A2 (ru) 2001-08-27
TR200302077T4 (tr) 2004-01-21
GB2356863A (en) 2001-06-06
HRP20000809A2 (en) 2001-12-31
EP1103545B1 (en) 2003-11-05
BG104992A (en) 2001-11-30
ZA200006964B (en) 2001-06-05
GB0028566D0 (en) 2001-01-10
ITMI20002575A1 (it) 2002-05-29
SI1103545T1 (en) 2004-02-29
BR0005616A (pt) 2001-07-17
BRPI0005616B8 (pt) 2021-07-06
AU7178700A (en) 2001-05-31
ATE253561T1 (de) 2003-11-15
ES2171134A1 (es) 2002-08-16
ID28483A (id) 2001-05-31
OA11513A (fr) 2004-02-03
IS5725A (is) 2001-05-29
JP3480835B2 (ja) 2003-12-22
GT200000197A (es) 2002-05-22
NO20006012L (no) 2001-05-30
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
YU73400A (sh) 2003-02-28
NO20006012D0 (no) 2000-11-28
ES2208205T3 (es) 2004-06-16
EP1103545A1 (en) 2001-05-30
SK285373B6 (sk) 2006-12-07
UA70326C2 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
NZ508386A (en) 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide for treating diseases associated with neurokinin-1 (NK-1) activity
HU9301051D0 (en) Method for producing (diaryl-methyl)-substituted n-oxydes of piperidine or piperazine derivatives and pharmaceuitcal preparatives containing said compounds
NZ331452A (en) use of 2-(4-indolyl-1-piperazinyl)alkylene-N-(2-pyridyl)-cyclohexane- carboxamide derivatives in treating central nervous system disorders
JO2371B1 (en) 4-phenyl-pyridine derivatives
BG106493A (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor
WO2002057252A3 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
MXPA05009508A (es) Derivados de nicotinamida 6-substituida como antagonistas de receptor opioide.
PT1129088E (pt) Forma cristalina de (r)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)- 2-piridinil]metil]sulfinil]-1h-benzimidazole
UA74419C2 (uk) Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
SG49283A1 (en) New compounds
MY117896A (en) Quinazoline derivatives
NZ515304A (en) Bradykinin receptor antagonists
NO20001514L (no) Vitronectin-reseptor-antagonist
NO20003211L (no) Triazinforbindelser for behandling av CNS forstyrrelser
BG104243A (en) Method for the synthesis of quinoline derivatives
MXPA03012039A (es) Derivados de benzo [g]quinolina para tratar glaucoma y miopia.
IL168416A (en) Process for the preparation of 2-aminomethylpyridine derivative
HU9600622D0 (en) Optically active imidazolidinone derivative and process for producing the same
MXPA03010943A (es) Proceso para preparar un ligando de ppar de tiazol y polimorfos del mismo.
AU8438798A (en) Use of draflazine-analogues for treating pain
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
HUP0401115A3 (en) 4-(benzylideneamino)-3-(methylsulfanyl)-4h-[1,2,4]triazin-5-one derivatives having a pde iv-inhibiting and tnf-antagonistic action for the treatment of heart diseases and allergies, process for their preparation and pharmaceutical compositions ...
NZ511411A (en) Benzisoxazoles and phenones as alpha2-antagonists
IL145585A0 (en) A process for preparing 1-phenyl-2-(2-pyridyl) ethanamine

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)